Verastem (VSTM) Cash & Equivalents Growth (1y) (2012 - 2026)

Verastem (VSTM) Cash & Equivalents Growth (1y) (2012 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. Growth (1y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 23.81%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - 15.53%
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 90.42%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 17.50%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -4.13%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 71.81%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Verastem 607.94 Mn 410.11 Mn 15.90 Mn 54.55%

Historic Data

Download Data
DateValue
Mar 31, 2026 54.55%
Dec 31, 2025 130.80%
Sep 30, 2025 21.68%
Jun 30, 2025 97.10%
Mar 31, 2025 44.58%
Dec 31, 2024 14.00%
Sep 30, 2024 19.15%
Jun 30, 2024 -54.46%
Mar 31, 2024 -16.39%
Dec 31, 2023 -1.48%
Sep 30, 2023 21.52%
Jun 30, 2023 186.30%
Mar 31, 2023 108.32%
Dec 31, 2022 5.73%
Sep 30, 2022 221.49%
Jun 30, 2022 156.09%
Mar 31, 2022 31.46%
Dec 31, 2021 10.34%
Sep 30, 2021 -85.74%
Jun 30, 2021 -80.07%